NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Reneo Pharmaceuticals, Inc. (RPHM) has a consensus analyst rating of Buy, based on 7 analysts covering the stock. Of those, 4 recommend buying, 3 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
